Balanced news tone
News Sentiment
GTBP sentiment intelligence
GT Biopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
56 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-16.3% over one week, -30.8% over four weeks, trend inactive, and below fair value.
GT Biopharma (GTBP) Stock Forecast & Analyst Ratings
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
-16.3%
Price reacting lower
Trend fit
Trend inactive
-30.8% over four weeks
Fair value
-88.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
42
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Moomoo
Direct company coverage
GT Biopharma (GTBP) Stock Forecast & Analyst Ratings
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 13 Jul 2026 16:11
- Source
- Moomoo
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
Moomoo
Direct company coverage
GT Biopharma (GTBP) Revenue Breakdown - Main Composition
The article "GT Biopharma (GTBP) Revenue Breakdown - Main Composition" is a placeholder document that suggests it's intended to detail the revenue composition of GT Biopharma. However, it currently contains no substantive content, indicating it is an empty or unwritten document.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 03:39
- Source
- Moomoo
Stock Titan
Direct company coverage
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan
GT Biopharma (GTBP) is proposing a reverse stock split, ranging from 1-for-10 to 1-for-30, along with a reduction in authorized common and preferred shares, to regain compliance with Nasdaq's minimum bid price requirement. The company is also seeking stockholder approval to incre
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 20:39
- Source
- Stock Titan
TradingView
Direct company coverage
Enterprise value to EBITDA forward of GT Biopharma, Inc. – NASDAQ:GTBP
This article provides an overview of the Enterprise Value to EBITDA forward for GT Biopharma, Inc. (NASDAQ: GTBP). It lists the company's stock market information and indicates that no trades have occurred, with the market appearing closed. The content is primarily a data placeho
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 13:14
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of GT Biopharma Inc – MUN:OXIA
This article provides financial information for GT Biopharma Inc (MUN:OXIA) on TradingView, specifically focusing on the enterprise value to EBITDA forward metric. The content, while primarily navigational and descriptive of the TradingView platform, indicates that the market was
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 04:39
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of GT Biopharma Inc – FWB:OXIA
This article provides financial data for GT Biopharma Inc (FWB:OXIA) on the Frankfurt Stock Exchange. It specifically highlights the "Price to book forward" metric, displayed within a seemingly data-driven interface provided by TradingView. The page indicates that the market is c
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 03:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of GT Biopharma Inc – FWB:OXIA
This article focuses on the "Enterprise value to revenue forward" metric for GT Biopharma Inc (FWB:OXIA) on the Frankfurt Stock Exchange, as presented on TradingView. It appears to be a financial data point without further analysis or detailed content presented in the provided te
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 20:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of GT Biopharma, Inc. – NASDAQ:GTBP
This article provides financial data for GT Biopharma, Inc. (NASDAQ: GTBP), specifically focusing on its enterprise value to EBIT forward. It indicates that the market is currently closed, and no trades have occurred for the stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 18:40
- Source
- TradingView
TradingView
Direct company coverage
GT Biopharma Inc Actuals & Estimates (SWB:OXIA)
This article provides an overview of GT Biopharma Inc (SWB:OXIA) financials and analyst estimates. It highlights key financial data such as earnings per share and revenue, upcoming earnings dates, and analyst price targets. The company's last reported earnings were -0.10 EUR per
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 07:40
- Source
- TradingView
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for GT Biopharma Inc (GTBP), noting its current risk assessment score of 1.27 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.79, indicating it tends to underperform during upward m
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 05:11
- Source
- TradingKey
TradingView
Direct company coverage
GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP)
This article provides an overview of GT Biopharma, Inc. (NASDAQ: GTBP) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent decline, an analyst price target of USD 3.00, and upcoming earnings report sc
- Tone
- Negative 29/100
- Event
- Analyst action
- Published
- 25 Jun 2026 16:10
- Source
- TradingView
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis
GT Biopharma Inc (GTBP) currently holds a valuation score of 6.85, placing it 284th out of 387 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.07, indicating a significant deviation from both its recent high and low P/E values. The article notes th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 11:10
- Source
- TradingKey
Intellectia AI
Direct company coverage
GTBP PE Ratio & Valuation, Is GTBP Overvalued
GT Biopharma Inc (GTBP) is currently in the "Fair zone" according to its forward PS ratio, which is considered fair compared to its five-year average. The company's current Price-to-Book (P/B) ratio is 2.54, significantly higher than its 3-year and 5-year averages, while its Forw
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 21:11
- Source
- Intellectia AI
AD HOC NEWS
Direct company coverage
GT Biopharma Stock - long-term cancer therapy strategy under review
GT Biopharma (GTBP) is an immuno-oncology developer focusing on its TriKE platform for treating difficult cancers. With no new market-moving news, the company's long-term strategy, clinical milestones, and financing needs for its clinical-stage pipeline are under investor scrutin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 18:09
- Source
- AD HOC NEWS
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for GT Biopharma Inc (GTBP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the stock's performance and market capitalization bu
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 20:39
- Source
- TradingKey
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of GT Biopharma Inc (GTBP), detailing its price momentum score, current trading range between support and resistance levels, and signals from various technical indicators. It highlights a "Buy" signal based on moving averages and other i
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 18 Jun 2026 07:41
- Source
- TradingKey
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of GT Biopharma Inc.'s (GTBP) shareholder structure, including major individual and institutional holders, and a categorized analysis of shareholder types. It also presents historical institutional shareholding data and recent shareholde
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 06:09
- Source
- TradingKey
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for GT Biopharma Inc (GTBP), highlighting its current earnings forecast score of 8.00 and an average analyst price target of $8.00. Based on one analyst's rating, the stock currently holds a "Buy" trend. The report also includes past and
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 23:09
- Source
- TradingKey
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Institutional Confidence
This article provides an overview of institutional confidence in GT Biopharma Inc (GTBP), detailing shareholdings and changes for key institutional investors. As of June 17, 2026, the company's institutional confidence score was 3.00, with notable increases in holdings by Bristol
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jun 2026 19:09
- Source
- TradingKey
TradingKey
Direct company coverage
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of GT Biopharma Inc (GTBP), reporting its current financial score as 7.52, ranking it 111 out of 388 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating efficiency. Key finan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:09
- Source
- TradingKey
Minichart
Direct company coverage
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing
GT Biopharma, Inc. recently filed an 8-K announcing an amendment to its bylaws, reducing the quorum requirement for shareholder meetings from a majority to one-third of outstanding shares. This change, effective June 8, 2026, aims to facilitate corporate actions due to difficulti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 13:09
- Source
- Minichart
Stock Titan
Direct company coverage
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third
GT Biopharma (NASDAQ: GTBP) has amended its bylaws to reduce the shareholder meeting quorum requirement from a majority to one-third of outstanding voting shares. This change, effective June 8, 2026, aims to make it easier for the company to achieve a quorum and conduct sharehold
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 20:08
- Source
- Stock Titan
AD HOC NEWS
Direct company coverage
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline
GT Biopharma received FDA clearance for its new IND for the GTB-5550 TriKE program, targeting B7-H3 in solid tumors. This development expands its immuno-oncology pipeline and draws attention from speculative biotech investors. As a clinical-stage micro-cap company, GT Biopharma's
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 09 Jun 2026 17:23
- Source
- AD HOC NEWS
The Manila Times
Direct company coverage
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
GT Biopharma (Nasdaq: GTBP), an immuno-oncology company, has advanced three TriKE candidates into human trials, including a recent expansion into solid tumors, yet its market valuation remains modest compared to peers. The company's proprietary TriKE platform utilizes natural kil
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jun 2026 03:39
- Source
- The Manila Times
Sahm
Direct company coverage
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
GT Biopharma, Inc. (NASDAQ: GTBP), a company with a valuation often under $20 million, has advanced its third drug, GTB-5550, into Phase 1 clinical trials for solid tumors. This milestone reflects the company's progress in leveraging its TriKE® platform beyond blood cancers, repr
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 03 Jun 2026 01:39
- Source
- Sahm
Sahm
Direct company coverage
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma (NASDAQ: GTBP) announced that its integration of AI-based technologies is significantly enhancing drug discovery productivity and pipeline development. The company anticipates these AI initiatives will accelerate the advancement of new development candidates into pre
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 02 Jun 2026 01:39
- Source
- Sahm
GlobeNewswire
Direct company coverage
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
GT Biopharma Provides Update on Pipeline Discovery
GT Biopharma announced updates on its AI-based technological initiatives, which are accelerating the discovery and engineering of tumor-targeting engagers and multi-domain proteins. These efforts are expected to lead to new development candidates entering pre-IND development in 2
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 01 Jun 2026 12:09
- Source
- GlobeNewswire